This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ ... / /
/ ... / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

 

 

Although a week’s dose is given in only one injection, the injection volume is the same as once-daily basal insulins.2 This is because the concentration of Awiqli® is 700 units/mL,1 equivalent to the concentration of glargine U100 or degludec U100, enabling the volume to be the same.2

 

After injection, the strong, reversible binding to albumin creates an essentially inactive albumin-bound depot. This is widely distributed throughout the circulation, from which Awiqli® is gradually and continuously released.1,2

For Awiqli®, the titration algorithm is similar to that of daily basal insulins. Patients will need to give their healthcare provider three consecutive days of pre-breakfast SMBG values or add them to their dose guidance app, which can be offered alongside Awiqli® for patients with type 2 diabetes.3
Record Only

After the initial starting dose of Awiqli®, the dose should then be increased or decreased from week 2 onwards, using a familiar titration concept* for basal insulins, to help your patient reach their target range. Titration should be based on the patient’s metabolic needs, blood glucose monitoring results and glycaemic control goal, until the desired FPG goal is achieved.1
Titrate up

 

If your patients with type 2 diabetes or type 1 diabetes are already on a conventional daily basal insulin therapy, but you think they may benefit from switching to once-weekly dosing with Awiqli®, please speak to your local sales representative or visit the booth at EASD.
Awiqli dosing

 

More insulin-naïve patients with
type 2 diabetes reach HbA1c
<7% without hypoglycaemia†2,3

 

Reduces basal insulin injections from 7 to 1 per week1

 

Awiqli® can be offered with a dose guidance solution such as Dose Check to support your patients 
with type 2 diabetes on their 
insulin journey.

1.

Awiqli® (insulin icodec). Summary of Product Characteristics. Novo Nordisk A/S. [June 2024].

2.

Nishimura E, et al. BMJ Open Diab Res Care 2021; 9:e002301.

3.

Philis-Tsimikas A, et al. Diabetes Obes Metab 2023; 25:331–341.

4.

Zinman B, et al. Diabetes Spectr 2012; 35:2464–2471.

5.

Philis-Tsimikas A, et al. Diabetes Care 2013; 30:607–622.

6.

Meneghini L, et al. Diabetes Care 2013; 36:858–864.

7.

Gough SCL, et al. Adv Ther 2013; 36:2536–2542.

8.

Chun J, Strong J, Urquhart S. Diabetes Care 2019; 32:104–111.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.
The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of May 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.

 

HQ24AWQ00153, July 2024